

Shingles Vaccine Market, 2012 to 2023

https://marketpublishers.com/r/S9F46D4A224EN.html Date: December 2017 Pages: 211 Price: US\$ 4,400.00 (Single User License) ID: S9F46D4A224EN

Abstracts

Market Outline: Shingles Vaccine Market

Shingles is known as Herpes Zoster which causes a blistering painful rash on the skin which lasts from 2 to 4 weeks. But, for some people, the pain may last for months or years. This pain is called as (PHN) Post Herpetic Neuralgia, which is a common complication of shingles and it's occurrence increases with age.

Market Dynamics: Shingles Vaccine Market

Increase in the prevalence and incidence of shingles disease around the world and increase in the global ageing population is expected to enhance the growth of shingles vaccine market across the globe. But, lack of awareness, high cost of the vaccination, unfavourable insurance coverage is major restraints of the global shingles vaccine market.

Market Scope: Shingles Vaccine Market

The Global Shingles Vaccine Market is classified on the basis of application, type, end user, and geographical regions.

Based on the type, global shingles vaccine market is segmented as

Live Vaccines Attenuated Vaccines

Based on the application, global shingles vaccine market is segmented as

Herpes Zoster Others

Based on the End User, global shingles vaccine market is segmented as



Hospitals

Clinic Others

Region Overview: Shingles Vaccine Market

There are safe and effective vaccines are available for prevention of shingles. In 2006, Merck & Co., Inc. licenced Zostavax for prevention of shingles which is intended for people above 50years of age. In 2016, GSK received FDA approval for its Shingrix, vaccine to prevent shingles which has 90% efficiency in people than zostavax. GSK filed regulatory approvals in Europe, Canada and Japan for Shingrix. Shingles vaccine market is a very high consolidated market with very few market players. It is experiencing a rapid growth due to the new products and it may gain swift in market growth due to the new entrants into the market during the forecast period.

Global Shingles Vaccine Market is segmented into Latin America, North America, Asia Pacific, The Middle East and Africa and Europe. North America is expected to dominate the market followed by Europe, owing to increase in population and rise in prevalence of shingles among population. While in Europe the market is expected to gain demand due to rise in the therapeutic demand from EU. Asia Pacific shingles vaccine market is expected to exhibit a rapid growth in shingles market due to presence of large untapped market areas and unmet needs especially in emerging economies, rise in health concerns, and increase in per capita income. Due to the limited awareness is the main restraint of the shingles vaccine market.

Competition Assessment: Shingles Vaccine Market

Some of the players in global shingles vaccine market

Merck& Co., Inc. (U.S.) GlaxoSmithKline plc (UK) Cipla Inc. (India) Pfizer Inc. (U.S.)



Contents

1. EXECUTIVE SUMMARY

2. GLOBAL SHINGLES VACCINE MARKET INTRODUCTION

- 2.1. Global Shingles Vaccine Market Taxonomy
- 2.2. Global Shingles Vaccine Market Definitions
- 2.2.1. Product Type
- 2.2.2. End User

3. GLOBAL SHINGLES VACCINE MARKET DYNAMICS

- 3.1. Drivers
- 3.2. Restraints
- 3.3. Opportunities/Unmet Needs of the Market
- 3.4. Trends
- 3.5. Global Shingles Vaccine Market Dynamics Factors Impact Analysis
- 3.6. Global Shingles Vaccine Market Regulations
 - 3.6.1. U.S
 - 3.6.2. Europe
 - 3.6.3. Japan
 - 3.6.4. China
- 3.7. Global Shingles Vaccine Market Product Innovations

4. GLOBAL SHINGLES VACCINE MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

- 4.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
- 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
- 4.3. Market Oppurtunity Analysis

5. GLOBAL SHINGLES VACCINE MARKET, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Product Type Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

- 5.1.1. Live Vaccines
 - 5.1.1.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD



Mn)

- 5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 5.1.1.3. Market Opportunity Analysis
- 5.1.2. Attenuated Vaccines

5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.2.3. Market Opportunity Analysis

6. GLOBAL SHINGLES VACCINE MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023

- 6.1. Herpes Zoster
- 6.1.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
- 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 6.1.3. Market Opportunity Analysis
- 6.2. Others
 - 6.2.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
 - 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 6.2.3. Market Opportunity Analysis

7. MARKET OPPORTUNITY ANALYSIS GLOBAL SHINGLES VACCINE MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023

- 7.1. Hospitals
 - 7.1.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
 - 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 7.1.3. Market Opportunity Analysis
- 7.2. Clinics
- 7.2.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
- 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 7.2.3. Market Opportunity Analysis
- 7.3. Others
- 7.3.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
- 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 7.3.3. Market Opportunity Analysis

8. GLOBAL SHINGLES VACCINE MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023



8.1. North America

- 8.1.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
- 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.1.3. Market Opportunity Analysis

8.2. Europe

- 8.2.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
- 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.2.3. Market Opportunity Analysis
- 8.3. Asia-Pacific
- 8.3.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
- 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.3.3. Market Opportunity Analysis
- 8.4. Latin America
- 8.4.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
- 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

- 8.5.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
- 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.5.3. Market Opportunity Analysis

8.6. Global Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Application Type, End User, and Region, 2017 – 2023

9. NORTH AMERICA SHINGLES VACCINE MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1.1. Live Vaccines

9.1.1.2. Attenuated Vaccines

9.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.2.1. Herpes Zoster

9.1.2.2. Others

9.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.3.1. Hospitals

9.1.3.2. Clinics



9.1.3.3. Others

9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.1.4.1. U.S.

9.1.4.2. Canada

9.1.5. North America Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Application, End User and Country, 2017 – 2023

9.1.6. North America Shingles Vaccine Market Dynamics - Trends

10. EUROPE SHINGLES VACCINE MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1.1. Live Vaccines

10.1.1.2. Attenuated Vaccines

10.1.2. Application Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.2.1. Herpes Zoster

10.1.2.2. Others

10.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.3.1. Hospitals

10.1.3.2. Clinics

10.1.3.3. Others

10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.4.1. Germany

- 10.1.4.2. UK
- 10.1.4.3. France
- 10.1.4.4. Spain
- 10.1.4.5. Italy
- 10.1.4.6. Russia
- 10.1.4.7. Poland
- 10.1.4.8. Rest of Europe

10.1.5. Europe Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, End User, and Country, 2017 – 2023

10.1.6. Europe Shingles Vaccine Market Dynamics - Trends



11. ASIA-PACIFIC SHINGLES VACCINE MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1.1. Live Vaccines

11.1.1.2. Attenuated Vaccines

11.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.2.1. Herpes Zoster

11.1.2.2. Others

11.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue

(USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.3.1. Hospitals

11.1.3.2. Clinics

11.1.3.3. Others

11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

- 11.1.4.1. Japan
- 11.1.4.2. China
- 11.1.4.3. India
- 11.1.4.4. ASEAN
- 11.1.4.5. Australia & New Zealand
- 11.1.4.6. Rest of Asia-Pacific

11.1.5. Asia-Pacific Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, End User, and Country, 2017 – 2023

11.1.6. Asia-Pacific Shingles Vaccine Market Dynamics – Trends

12. LATIN AMERICA SHINGLES VACCINE MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1.1. Live Vaccines

12.1.1.2. Attenuated Vaccines

12.1.2. Application Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.2.1. Herpes Zoster



12.1.2.2. Others

12.1.3. End User Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.3.1. Hospitals

12.1.3.2. Clinics

12.1.3.3. Others

12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 12.1.4.1. Brazil
- 12.1.4.2. Mexico
- 12.1.4.3. Argentina
- 12.1.4.4. Venezuela
- 12.1.4.5. Rest of Latin America

12.1.5. Latin America Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Application, End User, and Country, 2017 – 2023

12.1.6. Latin America Shingles Vaccine Market Dynamics - Trends

13. MIDDLE EAST AND AFRICA SHINGLES VACCINE MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1.1. Product Type Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1.1. Live Vaccines

13.1.1.2. Attenuated Vaccines

13.1.2. Application Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.2.1. Herpes Zoster

13.1.2.2. Others

13.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.3.1. Hospitals

13.1.3.2. Clinics

13.1.3.3. Others

13.1.4. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.4.1. Gulf Cooperation Council (GCC) Countries

13.1.4.2. Israel

13.1.4.3. South Africa

13.1.4.4. Rest of MEA



13.1.5. MEA Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Application, End User, and Country, 2017 – 2023

13.1.6. MEA Shingles Vaccine Market Dynamics - Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings,

Key Developments, Strategies, and SWOT Analysis)

- 14.2.1. Merck& Co., Inc. (U.S.)
- 14.2.2. GlaxoSmithKline plc (UK)
- 14.2.3. Cipla Inc. (India)
- 14.2.4. Pfizer Inc. (U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS



I would like to order

Product name: Shingles Vaccine Market, 2012 to 2023

Product link: <u>https://marketpublishers.com/r/S9F46D4A224EN.html</u>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/S9F46D4A224EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970